Castle Biosciences
CSTL
175 hedge funds and large institutions have $1.46B invested in Castle Biosciences in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 73 increasing their positions, 54 reducing their positions, and 23 closing their positions.
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
35% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 54
13% more capital invested
Capital invested by funds: $1.29B → $1.46B (+$168M)
7% more funds holding
Funds holding: 163 → 175 (+12)
4.68% more ownership
Funds ownership: 80.7% → 85.38% (+4.7%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
80% less call options, than puts
Call options by funds: $2.37M | Put options by funds: $12.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$39.7M |
| 2 |
Select Equity Group
New York
|
+$27.1M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$22.3M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$21.7M |
| 5 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.6M |
| 2 |
Millennium Management
New York
|
-$17.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.3M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$10.1M |
| 5 |
RI
Redwood Investments
Boston,
Massachusetts
|
-$9.5M |
CSTL Hedge Fund Activity: Q1 2021 in Review
175 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2021, worth a combined $1.46B — up 13% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CSTL positions and 23 closed out — a net gain of 12 holders — while 73 added to existing stakes and 54 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $39.7M. The largest seller was Fidelity Investments, cutting an estimated $18.6M.
- 175 institutional investors held Castle Biosciences (CSTL) as of Q1 2021, up from 163 in Q4 2020.
- Funds reported $1.46B of Castle Biosciences stock for Q1 2021, up 13% quarter-over-quarter.
- 35 funds opened new Castle Biosciences positions in Q1 2021 and 23 closed out, a net change of +12 holders.
- The largest Castle Biosciences buyer in Q1 2021 was ARK Investment Management, an estimated $39.7M added.
- The largest Castle Biosciences seller in Q1 2021 was Fidelity Investments, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2021.